Phase 1 Study to Evaluate the Safety and Tolerability of VK2735

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 14, 2021

Primary Completion Date

November 4, 2024

Study Completion Date

December 3, 2024

Conditions

Weight LossNASH

Interventions

BIOLOGICAL

VK2735

Administered SC

BIOLOGICAL

Placebo

Administered SC

DRUG

VK2735 Placebo

Administered orally

DRUG

VK2735 Drug

Administered orally

Trial Locations (1)

Viking Clinical Site, Adelaide

All Listed Sponsors

lead

Viking Therapeutics, Inc.

INDUSTRY

NCT05203237 - Phase 1 Study to Evaluate the Safety and Tolerability of VK2735 | Biotech Hunter | Biotech Hunter